Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Apoptotic Effects of Junglyeokdaejosape-tang and Junglyeok-tang on A549 lung Cancer Cells

A549 폐암 세포주에 대한 정력대조사폐탕 및 정력탕의 Apoptosis 효과

  • Yu Byeong-Gil (Department of Oriental Pathology, College of Oriental Medicine, Sangji University) ;
  • Kim Myung-Dong (Department of Oriental Physiology, College of Oriental Medicine, Sangji University) ;
  • Hwang Tae-Jun (Department of Oriental Physiology, College of Oriental Medicine, Sangji University) ;
  • Yoo Yeong-Min (Department of Oriental Pathology, College of Oriental Medicine, Sangji University) ;
  • Lee Seon-Goo (Department of Oriental Pathology, College of Oriental Medicine, Sangji University)
  • 유병길 (상지대학교 한의과대학 병리학교실) ;
  • 김명동 (상지대학교 한의과대학 생리학교실) ;
  • 황태준 (상지대학교 한의과대학 생리학교실) ;
  • 유영민 (상지대학교 한의과대학 병리학교실) ;
  • 이선구 (상지대학교 한의과대학 병리학교실)
  • Published : 2005.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer is one of the common malignant tumors in the world. It occurs more increasingly due to the serious air pollution, heavy smoking, expoure to ionized radiation, pollution with heavy metal, and owing to well advanced diagnostic skill, etc. Also lung cancer has the limitation of medical care because metastasis is already shown up in more than half cases when it is first detected through medical examination. Although it is treated with chemoradiation, the rate of deaths from lung cancer is high as well, because blood has a lot of toxicity which give side effects. So it has a low rate of cure. So, the ways of various treatment is being researched to raise the rate of care and decrease the side effects recently, and one of the results is inducing apoptosis which makes use of molecularbiologic diagnosis of lung cancer's cell and using oriental medicine drugs. The purpose of this study is whether apoptosis would happen on the human lung carcinoma cell by treated with Junglyeokdaejosape-tang, Junglyeok-tang Junglyeokdaejosape-tang and Junglyeok-tang has been prescribed for cough, chest pain, and many other similar cases. Cough and chest pain is shown in early lung cancer. That is why we used these prescriptions. Apoptosis happend on the human lung carcinoma A549 cells treated with Jeongiyeokdaejosapye-tang, Jeonglyeok-tang. The concentration-dependent inhibition of cell viability was observed and apoptosis was confirmed by DNA fragmentation. Bcl-2 and COX-2 mRNA expression decreased, but Bax mRNA expression increased, so it was identified with the case of indomethacin known to enhance apoptotic DNA fragmentation. Also expression of the p21, p53, cyclin E, cyclin D1, cytochrome c, caspase-3, and caspase-9 protein increased and the activity of caspase-3 increased, as well. Last, fragmentation of the PARP was shown. The previous and present results indicated that apoptosis of A549 cells by above-mentioned drugs is associated with the blockage of G1/S progression.

Keywords

References

  1. WHO. Cancer, WHO, http://www.who.int/cancer/en/, 2004.
  2. 강연이, 김태임, 박종오, 김성훈, 박종대, 김동희. 韓醫學의 抗腫瘍 免疫治療에 관한 연구-1990년 이후 발표된 실험논문을 중심으로, 동의생리병리학회지 17(1):1-24, 2003.
  3. 조완규. 腫瘍學, 서울, 서울대학교 출판부, pp 91-92, 1990.
  4. 이문호. 內科學, 서울, 금강출판사, pp 2466-2478, 1979.
  5. 조군제. 폐암의 치료방법, 대한내과학회지, 62(6):600-607, 2002.
  6. 田炳旭 외. 癌에 대한 韓醫學的 認識 및 實驗的 硏究에 관한 考察, 대한한방종양학회지 1(1):34-87, 1995.
  7. Ginsberg, R.J., Vokes, E.E., Raben, A. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology, 5th edit, Philadelphia: Lippincott-Raven, pp 858-911, 1997.
  8. 서울대학교 천연물과학연구소. 신동의약 개발사업 연구기획 최종보고서. pp 378-382, 1992.
  9. 한용철. 임상호흡기학, 서울, 일조각, p 137, 1995.
  10. 김성훈, 박경식, 유시용 : 생약복합제제 길경탕 및 가미길경탕의 항암효과(제 2보). 생약학회지 27(1):42-46, 1996.
  11. 김정범 편저. 金匱要略辨釋, 서울, 韓醫文化社, p 196. 2000.
  12. 朱 橚등 編. 普濟方, 中國醫學大系 Vol. 24. 도서출판 鼎談. pp 443-448.
  13. 통계청. 2000년 사망원인통계결과. 2001.
  14. 박재갑. 인간생명과학, 서울, 서울대학교출판부, pp 392-394, 1994.
  15. 김영환.폐암의 조기발견, 대한내과학회지 65(1):4-9, 2003.
  16. Bach, P.B., Kelley, M.J., Tate, R.V., McCrory, D.C. Screening for lung cancer: a review of the current literature, Chest 123, pp 72S-82S, 2003.
  17. Smith, R.A., Cokkinides, V., Eyre, H.J. American Cancer Society guidelines for the early detection of cancer, 2003. CA cancer J. Clin. 53, pp 27-43, 2003.
  18. Pignon, J.P., Arriagada, R., Ihde, D.C., Johnson, D.H., Perry, M.C., Souhami, R.L., Brodin, O., Joss, R.A, Kies, M.S., Lebeau, B, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer, N. Engl. J. Med. 327(23):1618-1624, 1992.
  19. Auperin, A., Arriagada, R., Pignon, J.P., Le Pechoux, C., Gregor, A., Stephens, R.J., Kristjansen, P.E., Johnson, B.E., Ueoka, H., Wagner, H., Aisner, J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341(7):476-484, 1999.
  20. Kris, M.G., Natale, R.B., Herbst, R.S., Lynch, T.J., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, C., Albain, K.S., Brahmer, J.R., Sandler, A., Crawford, J., Lutzker, S.G., Lilenbaum, R., Helms, L., Wolf, M., Averbuch, S., Ochs, J., Kay, A. A phase II trial of ZD1839('lressa') in advanced non-small cell lung cancer(NSCLC) patients who had failed platinum-and docetaxel-based regimens(IDEAL 2). Proceeding of ASCO 21, p 292a, 2002(abstr 1166).
  21. 조용선, 김시영, 김정희, 윤희중, 조경삼. 진행성 비소세포 폐암에서 Etoposide, Ifosfamide Cisplatin(VIP) 복합요법의 효과, J. Korean Cancer Assoc. 32(1):86-92, 2000.
  22. 김동희 외. 抗癌劑 및 放射線 副作用에 대한 韓方療法, 동의병리학회지 9, pp 240-249, 1994.
  23. 林鈞華 외. 중약 및 중약.방사선.화학 결합요법으로 원발성 간암 수술후 잔류와 재발을 치료함, 한글판 중의, p 46, 1994.
  24. 강병수, 고운채, 김선희, 노승현, 안병준, 신민교, 안덕균, 이상인, 이영종, 이강희, 주영승. 本草學, 서울, pp 484-486, 542-543, 1991.
  25. Evans, V.G. Multiple pathways to apoptosis. Cell Biol. Int. 17, pp 461-476, 1993.
  26. 김하원. 면역학사전, 서울, 서울시립대학교출판부, pp 37-39, 2001.
  27. Roose, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., Borner, C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391, pp 496-499, 1998.
  28. Surh, Y.J., Chun, K.S., Cha, H.H., Han, S.S., Keum, Y.S., Park, K.K., Lee, S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-$\kappa$B activation. Mutat. Res. pp 480-481, 243-268, 2001.
  29. Hidenobu, K., Hirotsugu, K., Hiroshi, S., Kunio, S. Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. European Journal of Phamacology 383, pp 331-337, 1999.
  30. Brandeis, M., Hunt, T. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J. 15. pp 5280-5289, 1996.
  31. Matsushime, H., Quelle, D.E., Shurtleff, S.A., Shibuya, M., Sherr, C.J., Kato, J.Y. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, pp 2066-2076, 1994.
  32. Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper , J.W., Elledge, S., Nishimoto, T., Morgan, D.O., Franza, B.R., Roberts, J.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257, pp 1689-1694, 1992.
  33. Elledge, S.J., Harper, J.W. CDK inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6, pp 847-852, 1994.
  34. Miyashita, T., Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, pp 293-299, 1995.
  35. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., Elledge, S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, pp 805-816, 1993.
  36. Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature 366, pp 701-704, 1993.
  37. Kluck, R.M., Bossy-Wetzel, E., Green, D.R., Newmeyer, D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, pp 1132-1136, 1997.
  38. Kaufmann, S.H., Desnoyers, S., Ottaviano, Y., Davidson, N.E., Poirier, G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53, pp 3976-3985, 1993.
  39. Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirier, G.G., Salvesen, G.S., Dixit, V.M. Yama/CPP32, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, pp 801-809, 1995.